HemCon Medical Technologies, Inc.

 

Stand no.  82

HemCon Medical Technologies, Inc.: Improving Care Through Innovative Infection Control Technology

In addition to providing hemostasis, HemCon dressings also offer an antibacterial barrier against a wide range of microorganisms including MRSA, VRE, and A. baumannii (only single strains of most species have been studied). This barrier may help decrease the risk of hospital acquired infection.

Showcase Content

The HemCon GuardIVa Antimicrobial Hemostatic IV Dressing is intended for use as a hydrophilic wound dressing to absorb exudate, cover and protect catheter sites. Common applications include IV catheters, other intravenous catheters and percutaneous devices.
It is also indicated for control of surface bleeding from percutaneous catheters and vascular access sites.Unlike other IV dressings, HemCon GuardIVa can be used in the first 24 hours after placement of any percutaneous device to control surface bleeding and provide antimicrobial protection. GuardIVa is the only IV dressing that provides hemostasis
and powerful antimicrobial protection in the critical 24 hours after placement and provides up to seven days of sustained antimicrobial activity.

Who are we targeting?

Acute Care Facilities

Why NHS staff should visit our showcase?

GuardIVa has demonstrated* sustained antimicrobial efficacy
against the main microorganisms responsible for CRBSI. Continuous
7-day efficacy may reduce the number of dressing changes needed
and therefore reduce the risk of exposing sites to infection.

Contact

tholmes@hemcon.com

www.hemcon.com

Partners

Cardinal Health, Zimmer Dental Inc., Zeria Pharmaceuticals Co. Ltd.,

Private label/exclusive distribution partners